Mutations of signaling molecules within the SHH pathway, such as SUFU, smoothened (SMO), PTCH1, GLI1 and GLI2, are defining, and they are commonly sought after as prime targets for small molecule inhibitors in medulloblastoma drug discovery [12,13,14,15,18,22]. This evidence concerns the gene SHH and medulloblastoma.